These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9843104)

  • 1. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis.
    Wolkenstein P; Latarjet J; Roujeau JC; Duguet C; Boudeau S; Vaillant L; Maignan M; Schuhmacher MH; Milpied B; Pilorget A; Bocquet H; Brun-Buisson C; Revuz J
    Lancet; 1998 Nov; 352(9140):1586-9. PubMed ID: 9843104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interventions for toxic epidermal necrolysis.
    Majumdar S; Mockenhaupt M; Roujeau J; Townshend A
    Cochrane Database Syst Rev; 2002; 2002(4):CD001435. PubMed ID: 12519556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide in toxic epidermal necrolysis.
    Klausner JD; Kaplan G; Haslett PA
    Lancet; 1999 Jan; 353(9149):324. PubMed ID: 9929047
    [No Abstract]   [Full Text] [Related]  

  • 4. Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN.
    Morales ME; Purdue GF; Verity SM; Arnoldo BD; Blomquist PH
    Am J Ophthalmol; 2010 Oct; 150(4):505-510.e1. PubMed ID: 20619392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Valeyrie-Allanore L; Wolkenstein P; Brochard L; Ortonne N; Maître B; Revuz J; Bagot M; Roujeau JC
    Br J Dermatol; 2010 Oct; 163(4):847-53. PubMed ID: 20500799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of histologic features of toxic epidermal necrolysis.
    Valeyrie-Allanore L; Bastuji-Garin S; Guégan S; Ortonne N; Bagot M; Roujeau JC; Revuz JE; Wechsler J; Wolkenstein P
    J Am Acad Dermatol; 2013 Feb; 68(2):e29-35. PubMed ID: 22088428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide in toxic epidermal necrolysis.
    Levy R
    Lancet; 1999 Jan; 353(9149):324. PubMed ID: 9929048
    [No Abstract]   [Full Text] [Related]  

  • 8. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    Jacobson JM; Greenspan JS; Spritzler J; Ketter N; Fahey JL; Jackson JB; Fox L; Chernoff M; Wu AW; MacPhail LA; Vasquez GJ; Wohl DA
    N Engl J Med; 1997 May; 336(21):1487-93. PubMed ID: 9154767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor alpha inhibitors in the treatment of toxic epidermal necrolysis.
    Woolridge KF; Boler PL; Lee BD
    Cutis; 2018 Jan; 101(1):E15-E21. PubMed ID: 29529123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia.
    Shannon E; Noveck R; Sandoval F; Kamath B; Kearney M
    Transl Res; 2007 Nov; 150(5):275-80. PubMed ID: 17964516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis.
    Bastuji-Garin S; Fouchard N; Bertocchi M; Roujeau JC; Revuz J; Wolkenstein P
    J Invest Dermatol; 2000 Aug; 115(2):149-53. PubMed ID: 10951229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial.
    Drenth JP; Vonk AG; Simon A; Powell R; van der Meer JW
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1221-6. PubMed ID: 11504824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.
    Abraham E; Anzueto A; Gutierrez G; Tessler S; San Pedro G; Wunderink R; Dal Nogare A; Nasraway S; Berman S; Cooney R; Levy H; Baughman R; Rumbak M; Light RB; Poole L; Allred R; Constant J; Pennington J; Porter S
    Lancet; 1998 Mar; 351(9107):929-33. PubMed ID: 9734938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
    Yang Y; Xu J; Li F; Zhu X
    Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines.
    Marriott JB; Cookson S; Carlin E; Youle M; Hawkins DA; Nelson M; Pearson M; Vaughan AN; Gazzard B; Dalgleish AG
    AIDS Res Hum Retroviruses; 1997 Dec; 13(18):1625-31. PubMed ID: 9430254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine.
    Kirchhof MG; Miliszewski MA; Sikora S; Papp A; Dutz JP
    J Am Acad Dermatol; 2014 Nov; 71(5):941-7. PubMed ID: 25087214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study.
    Paquet P; Jennes S; Rousseau AF; Libon F; Delvenne P; Piérard GE
    Burns; 2014 Dec; 40(8):1707-12. PubMed ID: 24726294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation.
    de Prost N; Mekontso-Dessap A; Valeyrie-Allanore L; Van Nhieu JT; Duong TA; Chosidow O; Wolkenstein P; Brun-Buisson C; Maître B
    Crit Care Med; 2014 Jan; 42(1):118-28. PubMed ID: 23989174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylprednisolone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers.
    Hirahara K; Kano Y; Sato Y; Horie C; Okazaki A; Ishida T; Aoyama Y; Shiohara T
    J Am Acad Dermatol; 2013 Sep; 69(3):496-8. PubMed ID: 23957982
    [No Abstract]   [Full Text] [Related]  

  • 20. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment.
    Schwartz RA; McDonough PH; Lee BW
    J Am Acad Dermatol; 2013 Aug; 69(2):187.e1-16; quiz 203-4. PubMed ID: 23866879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.